January 23, 2025 Company continues to do well and seems set for a good long term secular growth and performance. Management is equally focused on more geographies as well as more innovative products. Europe is the weak market currently. Americas are going ok. Management doesn’t seem to be concerned about Trump factor for now. India … Read more
January 27, 2025 Continued strong performance. Stock has become further expensive at 48x TTM P/E. The median P/E of the stock since listing in 2020 has been at 53x TTM P/E Don’t be in a hurry. Wait for good entry points. Company otherwise is a superb buy and hold. May 28, 2024 Strong performance during … Read more
February 10, 2025 Continued strong performance. Outlook remains strong based on management’s onground feelers. Exports have been slower compared to the expectation in the current year due to global headwinds. However, it should pick up going forward. Guidance remains same as 15-20% of total revenues vs less than 8% currently. Margins have been continuously improving. … Read more
August 21, 2024 Great potential of significant returns. February 13, 2024 During 9mths FY24, business performed as expected. Exhibition, food and Indrabrator businesses continues to show strong growth whereas IT parks nominal. Excitement trigger is missing. Valuations though continue to be attractive. August 6, 2023 Overall clean business and management. Debt free. Company had Rs … Read more
January 30, 2025 Continued strong performance Company has entered into two new therapies – Nephrology and Gynaecology Huge market but ramp up will take time as existing established players Ajanta confident of succeeding like it has demonstrated in other therapies Always open for acquisitions but so far has not found anything of fit at the … Read more
April 29, 2024 Going forward the performance is expected to improve due to industry dynamics. Surplus funds with the Company no plan to distribute it the shareholders will be used to fund organic and inorganic growth + a buffer against volatile WC requirements As always was a very good call with management’s focused control over … Read more